Zoledronic acid protects against bone density loss caused by antiretrovirals

Administering 5 mg of zoledronic acid at the start of antiretroviral therapy to HIV-infected patients who have never previously undergone ART can significantly decrease the risk of bone density loss....
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news